Group 1 - The controlling shareholder and chairman of the company, Qian Zhida, plans to reduce his stake by up to 3% of the total shares outstanding, which amounts to a maximum of 31.91 million shares [1][2] - The reduction will occur within three months after a 15 trading day period following the announcement, utilizing both centralized bidding and block trading methods [2] - The reason for the share reduction is personal funding needs, with the shares being sourced from those acquired before the company's initial public offering [2] Group 2 - The company has revised its plan for a private placement of A-shares five times, aiming to raise no more than 43.675 million yuan for a project to produce 1,150 tons of iodine contrast agent raw materials [3] - The issuance will involve no more than 35 specific investors, with the share price set at no less than 80% of the average trading price over the previous 20 trading days [3] - Following the issuance, the company's earnings per share and weighted average return on net assets may decline in the short term, indicating a potential dilution of immediate returns [3] Group 3 - The company forecasts a net profit attributable to shareholders of between 36 million yuan and 52 million yuan for the year 2024 [4]
002562，董事长拟减持